Skip to main
ATTO

ATTO Stock Forecast & Price Target

ATTO Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Attovia Therapeutics is taking a unique approach to biotechnology research and development by utilizing its ATTOBODY platform to design and develop optimized biologics targeting validated targets in the immune-mediated diseases space. This approach has been validated by the success of its lead product, ATTO-1310, which has shown promising early data and a clear roadmap for success in the treatment of high-itch indications like chronic pruritus and atopic dermatitis. Additionally, Attovia's pipeline includes ATTO-1091, a trispecific drug targeting three high-validated inflammatory bowel disease targets, which has shown promise in preclinical studies and has the potential to be a best-in-disease therapy. With a strong R&D engine and potential for both revenue and market growth, Attovia Therapeutics Inc represents a promising investment opportunity with significant upside potential.

Bears say

Attovia Therapeutics is a clinical stage biotechnology company with a focus on developing novel biologics targeting immune-mediated diseases. However, the company's limited pipeline and potential competition in the space pose risks for future commercialization and revenue generation. Additionally, concerns about the efficacy and dosing frequency of its lead asset, ATTO-1310, may lead to a downside revision in estimates, resulting in a fair value of $11.

ATTO has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Attovia Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Attovia Therapeutics Inc (ATTO) Forecast

Analysts have given ATTO a Buy based on their latest research and market trends.

According to 5 analysts, ATTO has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Attovia Therapeutics Inc (ATTO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.